FOXM1 is a molecular determinant of the mitogenic and invasive phenotype of anaplastic thyroid carcinoma

Endocrine-Related Cancer

Volumn 19, Issue 5, 2012, Pages 695-710

  Bellelli, Roberto ^a,b   Castellone, Maria Domenica ^a,b   Garcia Rostan, Ginesa ^c   Ugolini, Clara ^d   Nucera, Carmelo ^e   Sadow, Peter M ^f   Nappi, Tito Claudio ^a,b   Salerno, Paolo ^a,b   Cantisani, Maria Carmela ^a,b   Basolo, Fulvio ^d   Gago, Tomas Alvarez ^c   Salvatore, Giuliana ^g   Santoro, Massimo ^a,b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b CNR   (Italy)

^c UNIVERSITY OF VALLADOLID   (Spain)

^d UNIVERSITY OF PISA   (Italy)

^e BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g UNIVERSITY OF NAPLES PARTHENOPE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AURORA B KINASE; CYCLIN B1; FORKHEAD BOX PROTEIN M1; FORKHEAD TRANSCRIPTION FACTOR; PHOSPHATIDYLINOSITOL 3 KINASE; POLO LIKE KINASE 1; PROTEIN KINASE B; PROTEIN P53; S PHASE KINASE ASSOCIATED PROTEIN 2; TRANSCRIPTION FACTOR FKHRL1; UNCLASSIFIED DRUG; UROKINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL INVASION; CELL MOTILITY; CELL PROLIFERATION; CONTROLLED STUDY; DISTANT METASTASIS; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LOSS OF FUNCTION MUTATION; MITOGENESIS; MOUSE; NONHUMAN; PHENOTYPE; RNA INTERFERENCE; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA; UPREGULATION;

ANIMALS; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; CELLS, CULTURED; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; MICE; MICE, SCID; NEOPLASM INVASIVENESS; PHENOTYPE; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RNA INTERFERENCE; RNA, SMALL INTERFERING; THYROID GLAND; THYROID NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53; WOUND HEALING;

EID: 84867425304     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-12-0031     Document Type: Article

References (55)

1. Ahmad A, Wang Z, Kong D, Ali S, Li Y, Banerjee S, Ali R &Sarkar FH 2010 FoxM1 down-regulation leads to inhibition of proliferation, migration and invasion of breast cancer cells through modulation of extra-cellular matrix degrading factors. Breast Cancer Research and Treatment 122 337-346. (doi:10.1007/s10549-009-0572-1)
2. Ahmed M, Uddin S, Hussain AR, Alyan A, Jehan Z, Al-Dayel F, Al-Nuaim A, Al-Sobhi S, Amin T, Bavi P et al. 2012 FoxM1 and its association with matrix metalloproteinases (MMP) signaling pathway in papillary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 97 E1-E13. (doi:10.1210/jc. 2011-1506)
3. Barsotti AM & Prives C 2009 Pro-proliferative FoxM1 is a target of p53-mediated repression. Oncogene 28 4295-4305. (doi:10.1038/onc.2009.282)
4. Bhat UG, Halasi M & Gartel AL 2009 Thiazole antibiotics target FoxM1 and induce apoptosis in human cancer cells. PLoS ONE 4 e5592. (doi:10.1371/journal.pone.0005592)
5. Chiappetta G, De Marco C, Quintiero A, Califano D, Gherardi S, Malanga D, Scrima M, Montero-Conde C, Cito L, Monaco M et al. 2007 Overexpression of the S-phase kinase-associated protein 2 in thyroid cancer. Endocrine-Related Cancer 14 405-420. (doi:10.1677/ERC-06-0030)
6. Curcio F, Ambesi-Impiombato FS, Perrella G & Coon HG 1994 Long-term culture and functional characterization of follicular cells form adult normal human thyroids. PNAS 9 9004-9008. (doi:10.1073/pnas.91.19.9004)
7. Frisk T, Foukakis T, Dwight T, Lundberg J, Höög A, Wallin G, Eng C, Zedenius J & Larsson C 2002 Silencing of the PTEN tumor-suppressor gene in anaplastic thyroid cancer. Genes, Chromosomes & Cancer 35 74-80. (doi:10.1002/gcc.10098)
8. Garcia-Rostan G & Sobrinho-Simoes M 2011 Poorly differentiated thyroid carcinoma: an evolving entity. Diagnostic Histopathology 17 114-123. (doi:10.1016/j.mpdhp.2010.12.001)
9. Garcia-Rostan G, Zhao H, Camp RL, Pollan M, Herrero A, Pardo J, Wu R, Carcangiu ML, Costa J & Tallini G 2003 Ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. Journal of Clinical Oncology 21 3226-3235. (doi:10.1200/JCO.2003.10.130)
10. Garcia-Rostan G, Costa AM, Pereira-Castro I, Salvatore G, Hernandez R, Hermsem MJ, Herrero A, Fusco A, Cameselle-Teijeiro J & Santoro M 2005 Mutation of the PIK3CA gene in anaplastic thyroid carcinoma. Cancer Research 15 10199-10207. (doi:10.1158/0008-5472.CAN-04-4259)
11. Gimm O, Perren A, Weng LP, Marsh DJ, Yeh JJ, Ziebold U, Gil E, Hinze R, Delbridge L, Lees JA et al. 2000 Differential nuclear and cytoplasmic expression of PTEN in normal thyroid tissue, and benign and malignant epithelial thyroid tumors. American Journal of Pathology 156 1693-1700. (doi:10.1016/S0002-9440(10) 65040-7)
12. Halasi M & Gartel AL 2009 A novel mode of FoxM1 regulation: positive auto-regulatory loop. Cell Cycle 8 1966-1967. (doi:10.4161/cc.8.12.8708)
13. Hedinger C, Williams ED & Sobin LH 1989 The WHO histological classification of thyroid tumors: a commentary on the second edition. Cancer 63 908-911. (doi:10.1002/1097-0142(19890301)63:5〈908:: AIDCNCR2820630520〉3.0.CO;2-I)
14. Hegde NS, Sanders DA, Rodrigez R & Balasubramanian S 2011 The transcription factor FOXM1 is a cellular target of the natural product thiostrepton. Nature Chemistry 3 725-731. (doi:10.1038/nchem.1114)
15. Ito Y, Yoshida H, Nakano K, Takamura Y, Kobayashi K, Yokozawa T, Matsuzuka F, Matsuura N, Kuma K &Miyauchi A 2002 Expression of G2-M modulators in thyroid neoplasms: correlation of cyclin A, B1 and cdc2 with differentiation. Pathology, Research and Practice 198 397-402. (doi:10.1078/0344-0338-00272)
16. Jin N, Jiang T, Rosen DM, Nelkin BD & Ball DW 2009 Dual inhibition of mitogen-activated protein kinase kinase and mammalian target of rapamycin in differentiated and anaplastic thyroid cancer. Journal of Clinical Endocrinology and Metabolism 94 4107-4112. (doi:10.1210/jc.2009-0662)
17. Jin N, Jiang T, Rosen DM, Nelkin BD & Ball DW 2011 Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research 17 6482-6489. (doi:10.1158/1078-0432.CCR-11-0933)
18. Kalin TV, Wang IC, Ackerson TJ, Major ML, Detrisac CJ, Kalinichenko VV, Lyubimov A & Costa RH 2006 Increased levels of the FoxM1 transcription factor accelerate development and progression of prostate carcinomas in both TRAMP and LADY transgenic mice. Cancer Research 66 1712-1720. (doi:10.1158/0008-5472.CAN-05-3138)
19. Kalinichenko VV, Major ML, Wang X, Petrovic V, Kuechle J, Yoder HM, Dennewitz MB, Shin B, Datta A, Raychaudhuri P et al. 2004 Foxm1b transcription factor is essential for development of hepatocellular carcinomas and is negatively regulated by the p19ARF tumor suppressor. Genes and Development 18 830-850. (doi:10.1101/gad.1200704)
20. Kim IM, Ackerson T, Ramakrishna S, Tretiakova M, Wang IC, Kalin TV, Major ML, Gusarova GA, Yoder HM, Costa RH et al. 2006 The forkhead box m1 transcription factor stimulates the proliferation of tumor cells during development of lung cancer. Cancer Research 66 2153-2161. (doi:10.1158/0008- 5472.CAN-05-3003)
21. Kondo T, Ezzat S & Asa SL 2006 Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nature Reviews. Cancer 6 292-306. (doi:10.1038/nrc1836)
22. Korver W, Roose J & Clevers H 1997 The winged-helix transcription factor Trident is expressed in cycling cells. Nucleic Acids Research 25 1715-1719. (doi:10.1093/nar/25.9.1715)
23. Kwok JM, Myatt SS, Marson CM, Coombes RC, Constantinidou D & Lam EW 2008 Thiostrepton selectively targets breast cancer cells through inhibition of FOXM1 expression. Molecular Cancer Therapeutics 7 2022-2032. (doi:10.1158/1535-7163.MCT-08-0188)
24. Laoukili J, Kooistra MR, Bràs A, Kauw J, Kerkhoven RM, Morrison A, Clevers H & Medema RH 2005 FoxM1 is required for execution of the mitotic programme and chromosomal stability. Nature Cell Biology 7 126-136. (doi:10.1038/ncb1217)
25. Li Q, Zhang N, Jia Z, Le X, Dai B, Wei D, Huang S, Tan D &Xie K 2009 Critical role and regulation of transcription factor FoxM1 in human gastric cancer angiogenesis and progression. Cancer Research 69 3501-3509. (doi:10.1158/0008-5472.CAN-08-3045)
26. Liu M, Dai B, Kang SH, Ban K, Huang FJ, Lang FF, Aldape KD, Xie TX, Pelloski CE, Xie K et al. 2006 FoxM1B is overexpressed in human glioblastomas and critically regulates the tumorigenicity of glioma cells. Cancer Research 66 3593-3602. (doi:10.1158/0008-5472.CAN-05-2912)
27. Liu R, Liu D, Trink E, Bojdani E, Ning G & Xing M 2011 The Akt-specific inhibitor MK2206 selectively inhibits thyroid cancer cells harboring mutations that can activate the PI3K/Akt pathway. Journal of Clinical Endocrinology and Metabolism 96 E577-E585. (doi:10.1210/jc.2010-2644)
28. Liu R, Liu D & Xing M 2012 The Akt Inhibitor MK2206 synergizes, but perifosine antagonizes, the BRAFV600E inhibitor PLX4032 and the MEK1/2 inhibitor AZD6244 in the inhibition of thyroid cancer cells. Journal of Clinical Endocrinology and Metabolism 97 E173-E182. (doi:10.1210/jc.2011-1054)
29. McGovern UB, Francis RE, Peck B, Guest SK, Wang J, Myatt SS, Krol J, Kwok JM, Polychronis A, Coombes RC et al. 2009 Gefitinib (Iressa) represses FOXM1 expression via FOXO3a in breast cancer. Molecular Cancer Therapeutics 8 582-591. (doi:10.1158/1535-7163.MCT-08-0805)
30. Miller KA, Yeager N, Baker K, Liao XH, Refetoff S &Di Cristofano A 2009 Oncogenic Kras requires simultaneous PI3K signaling to induce ERK activation and transform thyroid epithelial cells in vivo. Cancer Research 69 3689-3694. (doi:10.1158/0008-5472.CAN-09-0024)
31. Nappi TC, Salerno P, Zitzelsberger H, Carlomagno F, Salvatore G & Santoro M 2009 Identification of Polo-like kinase 1 as a potential therapeutic target in anaplastic thyroid carcinoma. Cancer Research 69 1916-2223. (doi:10.1158/0008-5472.CAN-08-1693)
32. Nikiforov YE & Nikiforova MN 2011 Molecular genetics and diagnosis of thyroid cancer. Nature Reviews. Endocrinology 7 569-580. (doi:10.1038/nrendo. 2011.142)
33. Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F, Zhu Z, Giannini R, Salvatore G, Fusco A et al. 2003 BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. Journal of Clinical Endocrinology and Metabolism 88 5399-5404. (doi:10.1210/jc.2003-030838)
34. Nucera C, Nehs MA, Mekel M, Zhang X, Hodin R, Lawler J, Nose V & Parangi S 2009 A novel orthotopic mouse model of human anaplastic thyroid carcinoma. Thyroid 19 1077-1084. (doi:10.1089/thy.2009.0055)
35. Nucera C, Porrello A, Antonello ZA, Mekel M, Nehs MA, Giordano TJ, Gerald D, Benjamin LE, Priolo C, Puxeddu E et al. 2010 B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression. PNAS 107 10649-10654. (doi:10.1073/pnas.1004934107)
36. Nucera C, Nehs MA, Nagarkatti SS, Sadow PM, Mekel M, Fischer AH, Lin PS, Bollag GE, Lawler J, Hodin RA et al. 2011 Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer. Oncologist 16 296-309. (doi:10.1634/theoncologist.2010- 0317)
37. Pandit B, Halasi M & Gartel AL 2009 p53 negatively regulates expression of FOXM1. Cell Cycle 8 3425-3427. (doi:10.4161/cc.8.20.9628)
38. Radhakrishnan SK, Bhat UG, Hughes DE, Wang IC, Costa RH & Gartel AL 2006 Identification of a chemical inhibitor of the oncogenic transcription factor forkhead box M1. Cancer Research 66 9731-9735. (doi:10.1158/0008-5472. CAN-06-1576)
39. Raychaudhuri P & Park HJ 2011 FoxM1: a master regulator of tumor metastasis. Cancer Research 71 4329-4333. (doi:10.1158/0008-5472.CAN-11-0640)
40. Ricarte-Filho JC, Ryder M, Chitale DA, Rivera M, Heguy A, Ladanyi M, Janakiraman M, Solit D, Knauf JA, Tuttle RM et al. 2009 Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Research 69 4885-4893. (doi:10.1158/0008-5472.CAN-09-0727)
41. Saji M & Ringel MD 2010 The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors. Molecular and Cellular Endocrinology 321 20-28. (doi:10.1016/j.mce.2009.10.016)
42. Salvatore G, Nappi TC, Salerno P, Jiang Y, Garbi C, Ugolini C, Miccoli P, Basolo F, Castellone MD, Cirafici AM et al. 2007 A cell proliferation and chromosomal instability signature in anaplastic thyroid carcinoma. Cancer Research 67 10148-10158. (doi:10.1158/0008-5472.CAN-07-1887)
43. Santarpia L, El-Naggar AK, Cote GJ, Myers JN & Sherman SI 2008 Phosphatidylinositol 3-kinase/akt and ras/raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer. Journal of Clinical Endocrinology and Metabolism 93 278-284. (doi:10.1210/jc.2007-1076)
44. Schweppe RE, Klopper JP, Korch C, Pugazhenthi U, Benezra M, Knauf JA, Fagin JA, Marlow LA, Copland JA, Smallridge RC et al. 2008 Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. Journal of Clinical Endocrinology and Metabolism 93 4331-4341. (doi:10.1210/jc.2008-1102)
45. Smallridge RC, Marlow LA & Copland JA 2009 Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. Endocrine-Related Cancer 16 17-44. (doi:10.1677/ERC-08-0154)
46. Sorrentino R, Libertini S, Pallante PL, Troncone G, Palombini L, Bavetsias V, Spalletti-Cernia D, Laccetti P, Linardopoulos S, Chieffi P et al. 2005 Aurora B overexpression associates with the thyroid carcinoma undifferentiated phenotype and is required for thyroid carcinoma cell proliferation. Journal of Clinical Endocrinology and Metabolism 90 928-935. (doi:10.1210/jc.2004-1518)
47. Teh MT, Wong ST, Neill GW, Ghali LR, Philpott MP &Quinn AG 2002 FOXM1 is a downstream target of Gli1 in basal cell carcinomas. Cancer Research 62 4773-4780.
48. Volante M, Collini P, Nikiforov YE, Sakamoto A, Kakudo K, Katoh R, Lloyd RV, LiVolsi VA, Papotti M, Sobrinho-Simoes M et al. 2007 Poorly differentiated thyroid carcinoma: the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach. American Journal of Surgical Pathology 31 1256-1264. (doi:10.1097/PAS.0b013e3180309e6a)
49. Wang Z, Banerjee S, Kong D, Li Y & Sarkar FH 2007 Downregulation of forkhead box M1 transcription factor leads to the inhibition of invasion and angiogenesis of pancreatic cancer cells. Cancer Research 67 8293-8300. (doi:10.1158/0008-5472.CAN-07-1265)
50. Wiseman SM, Masoudi H, Niblock P, Turbin D, Rajput A, Hay J, Bugis S, Filipenko D, Huntsman D & Gilks B 2007 Anaplastic thyroid carcinoma: expression profile of targets for therapy offers new insights for disease treatment. Annals of Surgical Oncology 14 719-729. (doi:10.1245/s10434-006-9178- 6)
51. Wonsey DR & Follettie MT 2005 Loss of the forkhead transcription factor FoxM1 causes centrosome amplification and mitotic catastrophe. Cancer Research 65 5181-5189. (doi:10.1158/0008-5472.CAN-04-4059)
52. Wreesmann VB, Ghossein RA, Patel SG, Harris CP, Schnaser EA, Shaha AR, Tuttle RM, Shah JP, Rao PH &Singh B 2002 Genome-wide appraisal of thyroid cancer progression. American Journal of Pathology 161 1549-1556. (doi:10.1016/S0002-9440(10)64433-1)
53. Wu G, Mambo E, Guo Z, Hu S, Huang X, Gollin SM, Trink B, Ladenson PW, Sidransky D & Xing M 2005 Uncommon mutation, but common amplifications, of the PIK3CA gene in thyroid tumors. Journal of Clinical Endocrinology and Metabolism 90 4688-4693. (doi:10.1210/jc.2004-2281)
54. Xing M 2010 Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer. Thyroid 20 697-706. (doi:10.1089/thy.2010.1646)
55. Ye H, Kelly TF, Samadani U, Lim L, Rubio S, Overdier DG, Roebuck KA & Costa RH 1997 Hepatocyte nuclear factor 3/fork head homolog 11 is expressed in proliferating epithelial and mesenchimal cells of embryonic and adult tissues. Molecular and Cellular Biology 17 31626-31641.